{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.2","upperLimit":"80.9","value":"78.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"824"}],"units":"Participants"}],"description":"Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","dispersionType":"95% Confidence Interval","groups":[{"description":"All the eligible patients enrolled on the study","id":"OG000","title":"Total Patients"}],"paramType":"NUMBER","populationDescription":"As pre-specified in the protocol, this analysis includes all eligible patients (T-ALL+T-LLy) enrolled on the study.","reportingStatus":"POSTED","timeFrame":"3 years from start of therapy by patient","title":"Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}